Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

TWO-YEAR EFFECT AND SAFETY OF SEMAGLUTIDE 2.4 MG ONCE-WEEKLY IN SUBJECTS WITH OVERWEIGHT OR OBESITY (PROTOCOL VERSION 2.0, DATED 14 MAY 2018)

Intervention/treatment:
SEMAGLUTIDE S.C.
Medical condition:
OBESITY
Protocol code:
NN9536-4378
Control number:
212549
Status:
Closed
Approved:
June 15, 2018
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT03693430
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Clinical Reporting Office (1452)
Organization
Novo Nordisk A/S
Phone:
(+1) 866-867-7178
Sponsor
NOVO NORDISK CANADA INC

Locations

British Columbia

Novo Nordisk Investigational Site
Surrey, British Columbia, V3Z 2N6

New Brunswick

Novo Nordisk Investigational Site
Moncton, New Brunswick, E1G 1A7

Nova Scotia

Novo Nordisk Investigational Site
Halifax, Nova Scotia, B3H 1V7

Ontario

Novo Nordisk Investigational Site
Hamilton, Ontario, L8L 5G8
Novo Nordisk Investigational Site
Hamilton, Ontario, L8M 1K7
Novo Nordisk Investigational Site
Toronto, Ontario, M4G 3E8
Novo Nordisk Investigational Site
Toronto, Ontario, M4P 1P2
Novo Nordisk Investigational Site
Québec, Ontario, G1V 4G2

Quebec

Novo Nordisk Investigational Site
Montreal, Quebec, H4N 2W2

Results

See the results from the trial NCT03693430. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?